Fujifilm Corporation is investing $928 million to expand its large-scale biologics production facility in Denmark.
Specifically, the investment will bolster the Danish site of Fujifilm Diosynth Biotechnologies, a leading contract development and manufacturing organization (CDMO) for biologics and advanced therapies.
The capital investment will double the Denmark site’s current drug substance manufacturing capacity, and will expand its capabilities to include fill/finish, and enhance its current assembly, labelling and packaging services.
The investment will expand production lines for bulk drug substance with the addition of a further six mammalian cell bioreactors, bringing the total to 12 x 20,000-liter bioreactors by fall 2023, making the Denmark facility one of the few major large-scale manufacturing facilities in the bio-CDMO industry.
The development will also include the addition of the Denmark site’s first fill/finish production line (added by summer 2023), featuring a fully-automated, cutting-edge system capable of producing up to approximately 35 million units per annum to cater to large-scale production.
In spring 2022, a new packaging line equipped with facilities to assemble multiple types of auto-injectors as well as automatic labelling, will be added to meet a broad range of customer needs.
“Since the acquisition of the Denmark site last year, the facility’s strong manufacturing track-record, coupled with Fujifilm Diosynth Biotechnologies’ technologies enabling a stable supply of high-quality biopharmaceuticals, has led to new orders not only from existing clients, but also new clients, contributing to our rapid business expansion,” said Takatoshi Ishikawa, executive vice president, general manager of bio-CDMO division, Fujifilm Corporation.
In August 2019, Fujifilm invested approximately $890 million to acquire Biogen’s manufacturing subsidiary in Denmark, for its world-class cGMP capabilities and its experienced talent.
The advanced capabilities at the Denmark site has led to promising collaborations including the recent announcement of future manufacturing capacity reservation by the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed-up the response to the global pandemic.